AbbVie (NYSE:ABBV) is ticking up; according to a new Samsung Bioepis report, Humira's U.S. market share stays above 70% even with increasing biosimilar competition.
Losing U.S. exclusivity in early 2023, Humira, the top-selling arthritis medication from AbbVie, let biosimilars from Amgen (NASDAQ:AMGN), Teva (NYSE:TEVA), and Pfizer (NYSE:PFE) onto the market. After factoring over a third of AbbVie's income in 2022, Humira's share fell to 27% in 2023.
Humira still dominated 96% of the market as of February 2024, but its share dropped to 77% in May after several pharmacy benefit managers, notably CVS Health (CVS), kicked it off important formularies.AbbVie has 72% of the adalimumab market as of November 2024; biosimilars are taking center stage, rising from 2% to 23% in a year. Humira is still the leading market participant even with the evolving rivalry.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.